1. Lloyd-Jones DM, Wang TJ, Leip EP, et al. Lifetime risk for development of atrial fibrillation:

2. the Framingham Heart Study. Circulation. 2004;110(9):1042-6.

3. Camm AJ, Al-Khatib SM, Calkins H, et al. A proposal for new clinical concepts in the management of atrial fibrillation. Am Heart J. 2012;164(3):292-302.e1.

4. Hart RG, Pearce LA, Aguilar MI, et al. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007;146:857-67.

5. Fuster V, Rydén LE, Cannom DS, et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation--executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation). JACC 2006;48:854-906.

6. Ansell J, Hirsh J, Hylek E, et al. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008;133(6 Suppl):160S-98.

7. Ruff CT, Giugliano RP, Braunwald E, Antman EM. New oral anticoagulants in patients with atrial fibrillation — Authors’reply. Lancet. 2014;384(9937):25-6.

8. Connolly SJ, Ezekowitz MD, Yusuf S, et al.; Randomized Evaluation of Long-Term Anticoagulation Therapy Investigators. Newly identified events in the RE-LY trial. N Engl J

9. Med. 2010;363(19):1875-6.

10. Connolly SJ, Wallentin L, Yusuf S. Additional events in the RE-LY trial. N Engl J Med. 2014;371(15):1464-5.

11. Lauw M, How CH, Loh C. PILL Series. Deliberate self-harm in adolescents. Singapore Med J. 2015;56(6):306-8.

12. Eikelboom JW, Wallentin L, Connolly SJ, et al. Risk of bleeding with 2 doses of dabigatran

13. compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation. 2011;123(21):2363-72.

14. Graham DJ, Reichman ME, Wernecke M, et al. Cardiovascular, bleeding, and mortality risks in elderly Medicare patients treated with dabigatran or warfarin for nonvalvular atrial fibrillation. Circulation 2015;131(2):157-64.

15. Majeed A, Hwang HG, Connolly SJ, et al. Management and outcomes of major bleeding during treatment with dabigatran or warfarin. Circulation 2013;128(21):2325-32.

16. Schiele F, van Ryn J, Canada K, et al. A specific antidote for dabigatran: functional and structural characterization. Blood 2013;121(18):3554-62.

17. Glund S, Stangier J, Schmohl M, et al. Safety, tolerability, and efficacy of idarucizumab for the reversal of the anticoagulant effect of dabigatran in healthy male volunteers: a randomised, placebo-controlled, double-blind phase 1 trial. Lancet 2015;386(9994):680-90.

18. Pollack CV Jr, Reilly PA, Bernstein R, et al. Design and rationale for RE-VERSE AD: A phase

19. study of idarucizumab, a specific reversal agent for dabigatran. Thromb Haemost 2015; 114(1):198-205.

20. Niessner A, Tamargo J, Morais J. Reversal strategies for non-vitamin K antagonist oral anticoagulants: a critical appraisal of available evidence and recommendations for clinical management—a joint position paper of the ESC Working Group on Cardiovascular Pharmacotherapy and Working Group on Thrombosis. DOI: http://dx.doi.org/10.1093/eurheartj/ehv676 ehv676 First published online: 24 December 2015;114(1):198-205.